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Abstract: Nanomedicine concerns the use of precision-engineered nanomaterials to   develop 
novel therapeutic and diagnostic modalities for human use. The present study   demonstrates the 
efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dal-
ton’s lymphoma ascites (DLA) cell lines in vitro and in vivo. The AgNPs showed   dose-dependent 
cytotoxicity against DLA cells through activation of the caspase 3 enzyme, leading to induction 
of apoptosis which was further confirmed through resulting nuclear   fragmentation. Acute toxicity, 
ie, convulsions, hyperactivity and chronic toxicity such as increased body weight and abnormal 
hematologic parameters did not occur. AgNPs significantly increased the survival time in the 
tumor mouse model by about 50% in comparison with tumor controls. AgNPs also decreased 
the volume of ascitic fluid in tumor-bearing mice by 65%, thereby returning body weight to 
normal. Elevated white blood cell and platelet counts in ascitic fluid from the tumor-bearing 
mice were brought to near-normal range. Histopathologic analysis of ascitic fluid showed a 
reduction in DLA cell count in tumor-bearing mice treated with AgNPs. These findings confirm 
the antitumor properties of AgNPs, and suggest that they may be a cost-effective alternative in 
the treatment of cancer and angiogenesis-related disorders.
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Introduction
Nanobiotechnology, an emerging field of nanoscience, utilizes nanobased-systems 
for various biomedical applications. This rapidly developing field of nanoscience has 
raised the possibility of using therapeutic nanoparticles in the diagnosis and treatment 
of human cancers.1 Nanoscale particles and molecules are a potential alternative for 
treatment of disease because they have unique biologic effects based on their structure 
and size, which differ from traditional small-molecule drugs.2 In the last few years, 
several pharmaceutical companies have obtained approval from the US Food and Drug 
Administration (FDA) for the development of nanotechnology-based drugs. The global 
market for medical nanotechnology is expected to reach more than $3 billion within 
the next five years.3 A report based on a study by the European Science Foundation 
has stated that there is a need for large investment in developing new nanotechnology-
based medical tools for diagnostics and therapeutics.2
Silver was known only as a metal until the recent advent of the nanotechnology 
era, when it became recognized that silver could be produced at the nanoscale. Metal-
lic silver has been subjected to recent engineering technologies, resulting in ultrafine 
particles, the sizes of which are measured in nanometers (nm) and possess distinctive 
morphologies and characteristics.4,5International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Silver nanoparticles (AgNPs) are among the   emerging 
nanoproducts that have gained increasing interest in the 
field of nanomedicine due to their unique properties 
and   obvious therapeutic potential in treating a variety of 
  diseases, including retinal neovascularization,6,7 and acquired 
  immunodeficiency syndrome due to human   immunodeficiency 
virus (HIV).8,9 AgNPs are also known for their antimicrobial 
potential against several other viruses, including hepatitis 
B,10   respiratory   syncytial virus,11 herpes simplex virus type 
1,12 and monkey pox virus.13 AgNPs and ions have been 
shown to possess intrinsic cytotoxic activity14,15 and exhibit 
an enhanced antimicrobial effect when applied on silicon 
structures.16 Silver oxide   nanoparticles exhibited antitumor 
properties in transplanted Pliss lymphosarcoma tumor   models 
when administered by intravenous injection in the form of 
aqueous dispersions.17 Results of microbiologic studies indi-
cate that the interaction of silver ions with molecules of an 
extracellular lipoprotein matrix increases the permeability 
of the plasma membrane of microbial cells and eventually 
causes their death.18 AgNPs are synthesized by means of 
various physical, chemical, and biological methods. Even 
though the   chemical methods involve a very simple proce-
dure, they employ chemical reducing agents, such as citrate, 
borohydride, or other organic compounds,19,20 which are toxic 
to living organisms and hence render them unsuitable for 
medical use, whereas ecofriendly biologic synthesis involves 
formation of AgNPs by means of enzymatic reduction with 
better control over the shape and size of the nanoparticles.
AgNPs have also become a common component in cloth-
ing, food containers, wound dressings, ointments, and implant 
coatings,21,22 and some have already received approval from 
the FDA.23 Silver nanoparticles inhibit vascular endothelial 
growth factor (VEGF)-induced angiogenesis in bovine retinal 
endothelial cells.24 Similar studies have proven their inhibitory 
effect on vascular permeability induced by VEGF, interleukin 
(IL)-1β,25 and advanced glycation end product26 in retinal 
endothelial cells. The potent antiangiogenic and antiperme-
ability effects of AgNPs, along with their ability to halt tumor 
progression in Pliss lymphosarcoma cells, have prompted the 
study of the antitumor effect of AgNPs in ascitic tumors.
The aim of the present study was to determine the effects of 
biologically synthesized AgNPs on Dalton’s lymphoma ascites 
(DLA) tumorigenesis under in vitro and in vivo conditions.
Materials and methods
reagents and media
Streptomycin and penicillin were purchased from Calbiochem 
(La Jolla, CA). Fetal bovine serum (FBS) was   purchased 
from Sera Laboratories International Ltd (  Camarillo, CA). 
The MTT assay kit was purchased from Roche   Diagnostics 
(Mannheim, Germany). The caspase 3 assay kit was 
  purchased from Sigma (St. Louis, MO). Ischoves Modified 
Dulbeco’s Minimum Essential Medium (IMDM) was pur-
chased from Clonetics® (Walkersville, MD). Tissue culture 
dishes and 96 well plates were purchased from Falcon® 
(Franklin Lakes, NJ). Other chemicals were purchased from 
Sigma (St. Louis, MO) unless otherwise specified.
cell line
The DLA cell line was obtained from Amala Cancer Research 
Institute (Thrissur, India) and was propagated into trans-
plantable tumors in the peritoneal cavity of female Swiss 
albino mice. The freshly aspirated cells from the mouse 
peritoneum were washed with phosphate-buffered saline 
(PBS) under sterile conditions and their concentration was 
determined using a hemocytometer before transplantation. 
The   aseptically collected ascitic cells were washed with 
IMDM medium supplemented with FBS 10%, penicillin 
100 IU/mL, and streptomycin 100 mg/mL. The harvested 
DLA cells were incubated in a Petri dish for one hour at 
37°C in 5%, atmospheric CO2, and nonadherent cells were 
cultured and used for in vitro experiments.
Biosynthesis and purification of silver 
nanoparticles
The synthesis of AgNPs was carried out based on a method 
described elsewhere.27,28 Briefly, the bacterial cells were 
grown in nutrient broth (100 mL) containing beef extract 
(1 g), sodium chloride (0.5 g), and peptone (1 g) for 24 hours. 
After incubation, the cells were harvested by centrifugation 
(4000 × g, 10 minutes) and washed twice with sterile distilled 
water. Synthesis of AgNPs was carried out by taking 1 g of 
wet Bacillus licheniformis along with 1 mM of AgNO3 and 
making the reaction mixture up to 50 mL using deionized 
water in Erlenmeyer flasks which were then incubated in an 
incubator shaker at 37°C for 24 hours at 200 rpm.
Cells from the flasks were washed twice with 50 mM 
phosphate buffer (pH 7.0) and resuspended in 5 mL of the 
same buffer. Ultrasonic disruption of cells was carried out 
with an ultrasonic processor (Sonics Vibra Cell VC-505/220, 
Newtown, CT) over three 15-second periods, and with 
an interval of 45 seconds between periods. The sonicated 
samples were extracted and the resulting solution was filtered 
through a 0.22 µm Millipore filter to remove cellular debris. 
The sonicated samples were centrifuged at 16,000 × g for 
30 minutes at room temperature.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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characterization of silver nanoparticles
Characterization of the synthesized and purified AgNPs was 
carried out according to methods described   previously.29 
Samples for transmission electron microscopy (TEM) 
  analysis were prepared on carbon-coated copper TEM grids. 
TEM measurements were performed on a JEOL model 
1200EX instrument operated at an accelerating voltage of 
120 kV .
endotoxin assay
The Millipore H2O, used in all our experiments was tested 
for endotoxins using the gel clot method according to the 
  manufacturer’s instructions (LAL endotoxin assay kit). 
  Formation of a gel clot when the sample was treated   according 
to the kit manufacturer’s instructions indicated the   presence of 
endotoxin. Similarly, prior to treatment in mice, the nanopar-
ticle suspension in deionized water was checked for possible 
endotoxin contamination.
Determination of nanoparticle 
concentration
Accurate determination of the size and concentration of 
nanoparticles is essential for the biomedical application of 
nanoparticles.30 The concentration of AgNPs to be adminis-
tered at a nM level was determined by a method which has 
been previously reported.31 The calculation was as follows:
Initially the average number of atoms per nanoparticles 
was calculated using the formula:
 
N
D
N A =
πρ
3
6 M  
Where N = number of atoms per nanoparticle, π = 3.14, 
ρ = density of face-centered cubic silver = 10.5 g/cm3, D = 
average diameter of nanoparticles = 50 nm = 50 × 10−7 cm, 
M = atomic mass of silver = 107.868 g, NA = number of 
atoms per mole (Avogadro’s number = 6.023 × 1023). There-
fore, assuming 100% conversion of all silver ions to silver 
nanoparticles:
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ie, N = 3837233.003, then the molar concentration of the 
nanoparticle solution was determined by:
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Where C = molar concentration of the   nanoparticle solution, 
NT = total number of silver atoms added as AgNo3 = 1 M, N = 
number of atoms per nanoparticle (from above calculation), 
V = volume of the reaction solution in L, NA = Avogadro’s 
number (6.023 × 1023)
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Where C = 2.606 × 10−7 M/L = 2600 nM/10 mL. The required 
concentrations were thereafter made up from the obtained 
values.
MTT assay
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide dye reduction assay was performed to determine 
the cytotoxic effect of the AgNPs at various concentrations. 
The assay depends on the reduction of MTT by mitochondrial 
dehydrogenase, an enzyme present in the mitochondria of 
viable cells, to a blue formazan product. Briefly, the DLA cells 
were freshly harvested from DLA-bearing mice, and the cell 
concentration was adjusted to 1 × 105 cells/mL and plated onto 
96-well flat bottom culture plates with various concentrations 
of AgNPs. All cultures were incubated for 24 hours at 37°C in 
a humidified incubator. After 24 hours of incubation (37°C, 
5% CO2 in a humid atmosphere), 10 mL of MTT (5 mg/mL 
in PBS) was added to each well, and the plate was incubated 
for a further four hours at 37°C. The   resulting formazan was 
dissolved in 100 mL of   dissolving buffer (provided as part 
of the kit) and absorbance of the solution was read at 595 nm 
using a scanning   Multiwell spectrophotometer (Biorad, Model 
680, Japan). All determinations were carried out in triplicate. 
Concentrations of AgNPs showing 50% reduction in cell 
viability (ie, IC50 values) were then calculated.
caspase 3 assay
The cells were lysed with the lysis buffer provided in the 
caspase 3 assay kit (Sigma, St. Louis, MO) and kept on ice 
for 15–20 minutes. The assay is based on the hydrolysis of 
the peptide substrate, Ac-DEVD-pNA, by caspase 3,   resulting 
in the release of Ac-DEVD and p nitroaniline (pNA) which 
absorbs light significantly at 450 nm. Briefly, for 1 mL of the 
reaction mixture, 10 mL of the cell lysate from treated sam-
ples was added along with 980 mL of assay buffer,   followed 
by addition of 10 mL of 20 mM caspase 3   colorimetric sub-
strate (Ac-DEVD pNA). The cell lysates of the AgNP-treated 
DLA cells were then incubated at 37°C with the caspase 3 
substrate for two hours and the   absorbance was read at 450 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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nm in a double-beam ultraviolet Vis spectrophotometer 
(Shimadzu, Japan). The assay was also performed with non-
induced cells and in the presence of caspase 3 inhibitor for 
a comparative analysis.
DNA fragmentation assay
1 × 106 cells were lysed in 250 µL cell lysis buffer containing 
50 mM Tris HCl, pH 8.0, 10 mM ethylenediaminetetraacetic 
acid, 0.1 M NaCl, and 0.5% sodium dodecyl sulfate. The lysate 
was incubated with 0.5 mg/mL RNase A at 37°C for one hour, 
and then with 0.2 mg/mL proteinase K at 50°C overnight. 
Phenol extraction of this mixture was   carried out, and DNA 
in the aqueous phase was precipitated by 25 µL (1/10   volume) 
of 7.5 M ammonium acetate and 250 µL (1/1 volume) 
  isopropanol. DNA electrophoresis was performed in a 1% 
agarose gel containing 1 µg/mL ethidium bromide at 70 V , 
and the DNA fragments were visualized by exposing the gel 
to ultraviolet light, followed by photography.
Animal maintenance and tumor 
transplantation
The in vivo studies were conducted on female Swiss albino 
mice aged 5–6 weeks, weighing 25 ± 5 g, and housed in poly-
carbonate cages (five mice per cage) at an ambient temperature 
of 25 ± 2°C with a 12-hour light and 12-hour dark cycle. The 
mice were fed with commercially obtained rodent chow and 
water ad libitum. The animals were allowed to acclimatize to 
the laboratory environment and were then randomly   subjected 
to the experiment. All the experiments were carried out as 
per the guidelines of the institutional animal ethics committee 
(509/01/c/CPCSEA) and had prior approval from the same 
committee. The DLA cell lines were maintained in mice   models 
by aseptic serial transplantation in Swiss albino mice from 
tumor-bearing mice after the tenth day of ascites induction.
experimental design
The mice were divided into four groups, with six animals 
in each group: Group 1, blank nontumor mice (nontumor, 
untreated); Group 2, tumor control mice (tumor induced, 
untreated); Group 3, tumor-induced mice treated with AgNPs 
at a concentration of 500 nM in aqueous solution via intra-
peritoneal (IP) injection for 15 days; and Group 4, AgNP-
treated control mice at a concentration of 500 nM.
effect of silver nanoparticles  
on ascitic tumor
The minimum inhibitory concentration (IC50) determined by 
MTT assay was used for the in vivo experiments. The AgNP 
delivered to the mice was carried out using the IC50 obtained. 
Tumor mice in Group 3 were treated with AgNPs at a 
  concentration of 500 nM for a period of 15 days, and their 
ability to reduce tumor volume and the number of cells was 
compared with Group 2 tumor control mice.
Determination of mean survival time  
and percentage increase in lifespan
Animals were inoculated with 1 × 106 cells/mouse on 
day 0, and treatment with AgNPs started 24 hours after 
transplantation. The control group was treated with the same 
volume of 0.9% NaCl solution. All treatments were given for 
15 days. Mean survival time (MST) of each group, consisting 
of six mice, was noted. The antitumor efficiency of AgNPs 
was compared with that of 5-fluorouracil (Dabur Pharmaceu-
ticals, India) 20 mg/kg/day IP for nine days. The MST of the 
treated groups was compared with that of the control group 
using the following calculation:
  Increase in life span = (T − C/C) × 100
where T = number of days the treated animals survived and 
C = number of days the control animals survived.
euthanasia of experimental animals
After completion of the experimental treatment, all the mice 
were deprived of food overnight and euthanized by cervical 
dislocation under ketamine-xylazine anesthesia. The ascitic 
fluid and blood samples were collected carefully for various 
histologic and hematologic estimations, respectively.
hematologic analysis
Blood samples were collected by intracardiac puncture fol-
lowing anesthesia with ketamine-xylazine. Whole blood was 
immediately collected in ethylenediaminetetraacetic-coated 
vials for examination of potential hematologic toxicity. 
Hematology analysis included determination of white blood 
cell, red blood cell, and platelet levels, and measurement of 
mean corpuscular hemoglobin concentration and volume 
using an automated hematologic analyzer (MS9 Differential 
Cell Counter 3 Part, HD Consortium, India).
histologic analysis
Ascitic fluid plays a crucial role in DLA and is a collection 
of pleomorphic cells with hyperchromatic nuclei that are 
clumps of malignant cells. The viability of tumor cells in 
ascitic fluid can lead to further aggravation of disease, and 
hence the morphology and number of cells in ascitic fluid 
of the controls and tumor-treated mice were observed by International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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histologic analysis. The ascitic fluid was carefully collected 
from the two experimental groups (Group 2 and Group 3) 
and fixed at a concentration of 1 mL using a 10% formalin 
neutral buffer solution, embedded in paraffin, and cut into 
sections 5 µm thick. The sections were stained using hema-
toxilyn and eosin, examined under a light microscope, and 
photomicrographs obtained.
Statistical analysis
Values were expressed as mean ± standard deviation (SD). 
Statistical significance (5%) was evaluated by one-way 
analysis of variance (ANOVA) followed by Student’s t-test 
(P , 0.05, Graph Pad, San Diego, CA).
Results
characterization of silver nanoparticles
Prior to the study of the antitumor effect of AgNPs, character-
ization of synthesized AgNPs was performed. TEM showed 
that the purified nanoparticles were spherical with a mean 
diameter of 50 nm, and the LAL endotoxin assay revealed 
that the purified AgNPs were endotoxin-free.
effect of silver nanoparticles on tumor 
cell viability
The effect of AgNPs on viability of tumor cells was checked 
using the MTT assay. The AgNPs were able to reduce viability 
of the DLA cells in a dose-dependent manner, as shown in 
Figure 2. After six hours of treatment, the AgNPs were found 
to be cytotoxic to tumor cells at concentrations of 500 nM 
and higher. AgNPs at 500 nM decreased the viability of DLA 
cells to 50% of the initial level, and this was chosen as the 
IC50. Longer exposures resulted in additional toxicity to the 
cells. These results demonstrate that AgNPs mediate a con-
centration- and time-dependent increase in toxicity. Because 
a 500 nM concentration of AgNPs was found to be the IC50, 
further experiments were carried out using this concentration, 
to show the effect of AgNPs against the tumor under in vitro 
and in vivo conditions.
caspase 3 assay and effect  
on DNA fragmentation
Because the cellular metabolic activity seemed affected by 
the AgNPs, the possibility of apoptosis induction by the 
nanoparticles was assessed, especially at the IC50. Levels of 
50 nm 
Figure 1 Transmission electron microscopic image obtained from purified fractions 
collected after sucrose density gradient of silver nanoparticles synthesized using Bacillus 
licheniformis. Purified nanoparticles from B. licheniformis were examined by electron 
microscopy.27,28 Several fields were photographed and were used to determine the 
diameter of nanoparticles. The range of observed diameter was 50 nm.
0
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Figure 2 Dose-dependent effect of silver nanoparticles over cell viability using MTT assay. results are presented in relative units compared with controls. Data represent 
the mean ± standard error of the mean of three individual experiments. P , 0.05 compared with the control group.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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caspase 3, a molecule which plays a key role in the apoptotic 
pathway of cells, were increased following the treatment with 
AgNPs, as shown in Figure 3. The cell lysates obtained from 
DLA cells treated with 50 nm of AgNPs at 500 nM con-
centrations for six hours was used for this assay. Caspase 3 
activation suggested that AgNPs caused cell death through 
apoptosis, which was further supported by cellular DNA 
fragmentation. DNA ladders of the corresponding treated 
samples confirmed apoptosis (see Figure 4) and showed 
that the AgNP-treated DLA cells exhibited extensive double 
strand breaks, thereby yielding a ladder appearance (Lane 3), 
while the DNA of control DLA cells supplemented with 10% 
serum exhibited minimum breakage (Lane 2). The 1 kb ladder 
(Lane 1) was used to find the molecular weight of cleaved 
DNA fragments.
effect of AgNPs on survival rate in DLA 
tumor-bearing mice
The AgNPs confirmed to be endotoxin-free and of size 50 nm 
at 500 nM concentration exhibited remarkable anti-DLA 
activity. Administration of AgNPs IP for 15 days resulted in 
complete protection in four out of five DLA-challenged mice. 
Furthermore, the AgNPs prolonged the life span of treated 
tumor-bearing mice, which survived for 32 days compared 
with the untreated tumor controls which survived for only 
18 days from the first day of tumor induction (Table 1).
effect of silver nanoparticles on tumor 
volume and body weight
Treatment with AgNPs for a period of 15 days in DLA tumor-
bearing mice led to a significant reduction in tumor volume 
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Figure 3 Silver nanoparticles induce apoptosis in Dalton’s lymphoma ascites cells by caspase 3 activation.
*P , 0.05 versus controls, data were mean ± standard deviation calculated from three individual experiments (n = 3; *P , 0.01, **P , 0.001, ***P , 0.0001).
in comparison with tumor controls. Tumor volume in control 
mice was about 7.3 mL but was significantly reduced to 
2.6 mL in the group treated with AgNPs at a concentration of 
500 nM for 15 days. Body weight, measured throughout the 
period of the experiment, was reduced in the treated tumor-
bearing group when compared with the tumor control group 
(Table 2). The group of mice treated with AgNPs alone did 
not exhibit any abnormalities or reduction in body weight.
Figure 6 shows morphologic confirmation of the anti-
tumor activity of AgNPs by significant reduction in tumor 
volume in the IP region in comparison with the tumor control 
mice, thereby serving the tumor mice to regain its original 
weight.
hematologic analysis
The mice injected with AgNPs at a concentration of 500 nM 
for 15 days were examined daily for any changes in mor-
phology and behavior. All the mice survived throughout the 
experimental period without exhibiting any abnormalities. 
The mice did not exhibit any symptoms of toxicity, such as 
fatigue, loss of appetite, change in fur color, or weight loss. 
Comparative analysis of various hematologic parameters in 
the AgNP-treated mice and control animals clearly showed 
that there was no significant alteration except for marginal 
variations in some parameters that was still within the normal 
range (Table 3).
histologic analysis of DLA cells
Histologic analysis of DLA cells from peritoneal fluid 
revealed that AgNP treatment in tumor-bearing mice led to a 
significant reduction in the number of malignant cell clumps International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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for the treated group when compared with the control group 
(Figure 5), reflecting the potential of AgNPs to have cytotoxic 
effects in tumor cells, without affecting normal cells.
Discussion
AgNPs have been shown to have important antiangiogenic 
properties,32 so are attractive for study of their potential 
antitumor effects. Compounds possessing antiangiogenic 
properties are known for their potential ability to block the 
activity of abnormally expressed signaling proteins, such as 
Ras and Akt, cytokine-based therapies, DNA- or protein-
based vaccines against specific tumor markers, and tyrosine 
kinase inhibitors which exhibit a consistent antitumor effect.33 
In this study, AgNPs of size 50 nm at a concentration of 
500 nM had cytotoxic effects on DLA tumor cells under 
in vitro conditions as well as in an in vivo tumor model.
Initially, a dose-dependent effect of AgNPs on DLA 
cell lines assessed by MTT assay showed an IC50 value of 
about 500 nM that induced partial reduction in cell viability 
in comparison with controls. The cytotoxic effect of AgNPs 
on cell viability has a major role in antitumor activity, 
thereby reducing disease progression. This is consistent 
with the effect of AgNPs on cell viability during VEGF-
induced angiogenesis in retinal endothelial cells,34 thereby 
inhibiting the development of angiogenic retinal disorders or 
123
Figure 4 DNA fragmentation assay. Lane 1 (1 kb ladder), lane 2 (10% serum), and 
lane 3 (treated with silver nanoparticles).
Table 1 effect of silver nanoparticles on survival rate in DLA 
tumor-bearing mice
Treatment  
group 
Design of  
treatment 
Survival  
time (days) 
Increase in life   
span (T/C, %) 
1  control  50 (± 2)  – 
2  Tumor control  18 (± 1)  –
3  Tumor induced,  
treated with AgNPs
32 (± 3 )  77.78 
4 Treated  
with AgNPs
50 (± 5) –
each value represents the mean ± SD of n = 6
Abbreviations: AgNPs, silver nanoparticles; DLA, Dalton’s lymphoma ascites; SD, 
standard deviation.
Table 2 effect of silver nanoparticles on ascitic tumor volume and 
body weight
Treatment  
group
Design of  
treatment
Tumor  
volume  
(mL)
Average  
increase in  
body weight (g)
1 control – 23.2 (± 1.6)
2 Tumor control 7.3 (± 1.5) 42.4 (± 2.5)
3 Tumor induced,  
treated with AgNPs
2.6 (± 0.5) 29.6 (± 1.2)
4 Treated  
with AgNPs
– 22.8 (± 0.5)
each value represents the mean ± SD of n = 6.
Abbreviations: AgNPs, silver nanoparticles; SD, standard deviation.
Table 3 effect on silver nanoparticles on hematologic parameters
Parameters Control Tumor  
control
Tumor  
treated
hb (g/dL) 11.1 (± 0.18) 12.1 (± 0.37) 11.04 (± 0.53)
rBc distribution  
width (%)
18.8 (± 2.6) 17.5 (± 0.9) 19.4 (± 0.42)
McV (fL) 47.39 (± 0.5) 49.6 (± 2.4) 44.18 (± 5.3)
Mch (pg) 22.55 (± 4.26) 16.3 (± 3.74) 17.85 (± 1.54)
Mchc (g/dL) 31.16 (± 1.43) 32.8 (± 0.67) 34.87 (± 1.3)
Platelet count  
(×109/L)
275 (± 29.38) 1371 (± 2.8) 462 (± 15.57)
WBc (×109/L) 9.5 (± 2.37) 58.8 (± 5.43) 18.17 (± 6.2)
rBc (×1012/L) 4.65 (± 0.56) 7.45 (± 0.14) 9.34 (± 1.8)
Leukocytes  
(×109/L)
2.82 (± 0.21) 5.42 (± 2.43) 4.1 (± 0.87)
hcT (%) 33.17 (± 2.8) 37.0 (± 1.26) 29.65 (± 4.9)
each value represents the mean ± SD of n = 6.
Abbreviations: hb, hemoglobin; rBc, red blood cells; McV, mean corpuscular 
volume; Mch, mean corpuscular hemoglobin; Mchc, mean corpuscular hemoglobin 
content; hcT, hematocrit; SD, standard deviation. P values were calculated using 
one-way analysis of variance followed by Student’s t-test by comparison of groups 
(control versus treatment) and values considered to be significant at P , 0.05.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 5 histologic analysis of ascitic cells in animal models. A) Smear showing numerous clumps of pleomorphic cells with hyperchromatic nuclei that are malignant cell 
clumps (tumor controls). B and C) Smears show very few pleomorphic cells with hyperchromatic nuclei and significant reduction in malignant cell clumps in comparison 
with A (tumor, treated group).
  complications. The cytotoxic effects of silver are the result 
of active physicochemical interaction of silver atoms with 
the functional groups of intracellular proteins, as well as with 
the nitrogen bases and phosphate groups in DNA.35 In order 
to clarify the mechanism by which AgNPs exert a cytotoxic 
effect in tumor cells, a caspase 3 enzyme calorimetric assay 
was performed which showed that the antitumor activity was 
mediated by induction of apoptosis activated by the caspase 3 
enzyme. The DNA fragmentation experiments subsequently 
confirmed that induction of apoptosis was triggered by acti-
vation of caspase 3.
The major criteria to be taken into consideration for any 
potential anticancer drug are its efficacy in prolongation of 
lifespan and decrease of tumor volume and viable tumor cell 
count.36 In the present study, IP inoculation of DLA cells in 
mice produced a marked increase in the cancer cell count 
which indicated tumor progression in the animals, whereas 
a substantial decrease in cancer cell numbers in the treated 
tumor mice observed through histopathologic analysis clearly 
showed that AgNPs had a significant inhibitory effect on 
tumor cell proliferation and survival. The effect of AgNPs 
in increasing mean survival time and life span (as shown in 
Table 1) depends on their ability to reduce tumor cell viability 
and induce cytotoxicity.
The prime feature of tumor development is the escape 
of cells from programmed cell death due to a metabolic 
abnormality or genetic mutation. Thus, another criterion for 
anticancer drug development is the ability of a compound 
to induce apoptosis in cancer cells.37 This ability has been 
shown for AgNPs in the present study. The increase in tumor 
weight in Group 2 in our experiment may be due to accu-
mulation of peritoneal fluid given the abnormal enlargement 
of the peritoneal cavity observed in tumor-bearing mice. 
Treatment with AgNPs reduced tumor weight and hence 
increased life span. The hematologic parameters examined 
in the controls, tumor controls, and tumor-treated mice show 
the effect of AgNPs in reducing white blood cell and platelet 
counts in tumor-bearing mice compared with controls. These 
data highlight the nontoxic effect of AgNPs, which did not 
induce any alteration in hematologic parameters for treated 
mice in comparison with controls and, at the same time, 
led to effective control of white blood cells that possess the 
immunologic constituents of ascitic fluid.
One feature of DLA tumor growth related to the progres-
sion of angiogenic complications is enlargement of the cross-
sectional area of peritoneal microvessels. The formation of 
enlarged microvessels early in the course of ascites tumor 
angiogenesis may relate to the fibrin stroma in which these 
A  B 
Figure 6 Antitumor activity of silver nanoparticles in a Dalton’s lymphoma ascites 
mice model. A significant reduction in body weight and tumor volume in the peritoneal 
region following treatment with silver nanoparticles in comparison with controls. 
Key: A) tumor control; B) tumor mice treated with silver nanoparticles for 15 days.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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vessels develop.38 Tumor cells implanted into the peritoneal 
cavity secrete vascular permeability   factor and thereby render 
the microvasculature supplying the peritoneal lining tissues 
hyperpermeable.39 With respect to vascular   hyperpermeability, 
the ascites tumor model used in the present study   resembles 
a solid tumor model, with angiogenesis and generation of 
a connective tissue stroma. AgNPs that have been proven 
to delay tumor progression in DLA cell lines and tumor 
models in vivo may have a potent   antipermeability effect by 
inhibiting tubular formation in growth factor- and advanced 
glycation end product-induced vascular   permeability and 
cytotoxic effects that inhibit existence of tumor cells, which 
may be due to their potent activation of the caspase enzyme, 
as demonstrated in this study. The role of AgNP in inhibiting 
DLA cell viability and proliferation will be similar to their 
potential to inhibit the permeability of endothelial cells by 
inactivating Src kinases which have been proven to have a 
role in retinal therapies.16 The pathways by which AgNPs 
inhibit the pathway mediating cell proliferation and viability 
have yet to be explored.
AgNPs serve as antitumor agents by decreasing progres-
sive development of tumor cells. This may be due to their 
inhibitory activities in several signaling cascades responsible 
for the development and pathogenesis of the disease which 
are as yet not understood.
Taken together, our data suggest that AgNPs can induce 
cytotoxic effects on DLA cells, inhibiting tumor   progression 
and thereby effectively controlling disease progression with-
out toxicity to normal cells.
Conclusion
It is predicted that nanotechnology will have a $3.1 trillion 
impact on the global economy by 2015.40 The projected nano-
technology market is expected to be about US$25   billion (or 
�15 billion) in 2012.41 Use of AgNPs should emerge as one of 
the novel approaches in cancer therapy and, when the molecular 
mechanism of targeting is better understood, the applications 
of AgNPs are likely to expand further.42 The present study 
explores the potential antitumor activity of biologically syn-
thesized AgNP in a DLA tumor system in vitro by activation of 
the caspase 3 enzyme which is known to have a potent inhibi-
tory effect on disease progression in a mouse model, leading 
to a potent restorative effect in the treated tumor mice near to 
normal by reducing tumor volume and weight gain. These drug 
delivery systems are mainly developed according to their abil-
ity to differentiate between malignant and nonmalignant cells, 
making them a promising alternative to existing drugs. This 
type of targeting efficiency of AgNPs can be accomplished in 
future   therapies using RGD peptide conjugation, which directly 
targets tumor cells without affecting normal cells. Thus, a study 
of the exact mechanism by which AgNPs inhibit signaling 
cascades responsible for the development and progression of 
the disease would be a tremendous breakthrough in the field of 
nanomedicine and make these agents an effective alternative 
in tumor and angiogenesis-related diseases.
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